FDA approves ICD and CRT-D devices with Bluetooth technology for remote monitoring
The U.S. Food and Drug Administration (FDA) approved implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, according to a press release by Abbott.
The next-generation device (Gallant) offers Bluetooth technology, allowing a patient to connect to a smartphone app for remote monitoring and better patient/physician engagement.
The devices are intended for patients with heart rhythm disorders.
“We are focused on developing and delivering life-changing technologies that impact patient care in a meaningful way,” said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott, in the press release. “The Gallant devices are the latest example of how Abbott is driving innovation to meet changing healthcare needs and helping to improve connectivity and engagement between patients and their doctors.”
Read the full press release here.
